Cagrilintide: the amylin pathway in metabolic research

NŪVO Insights · Emerging science. Clearly explained.

Why this research programme differs from GLP-1 alone, and why CagriSema results need their own interpretation.

The science of appetite extends beyond a single hormone. Researchers are investigating several biological signals and asking whether acting on different pathways can improve metabolic treatment. Cagrilintide is part of that work, with a focus on amylin-related signalling.

Some supplier libraries use the shorthand “CAG”. For a scientific discussion, cagrilintide is the clearer term. It helps readers find the correct trials and avoids treating a commercial abbreviation as a precise description of an authorised medicine.

An additional pathway, not another name for GLP-1

Cagrilintide is a long-acting amylin analogue. Amylin and GLP-1 belong to different signalling systems, even though both are relevant to research on food intake and metabolism. Structural research has investigated how cagrilintide interacts with calcitonin and amylin receptor complexes. ^[2]

This receptor work helps explain the molecule’s pharmacology. It is not a clinical ranking system: identifying another target does not automatically demonstrate greater benefit or fewer adverse effects. Those questions need studies in people.

The combination called CagriSema brings cagrilintide together with semaglutide. It is therefore important to check whether a headline concerns cagrilintide alone or the combined intervention. A trial of two active components answers a different question from a trial of one.

What the clinical programme has examined

A phase 2 study published in 2021 evaluated cagrilintide for weight management in people with overweight or obesity. Its randomised design included placebo and an active comparator. Weight reductions exceeded those with placebo, while gastrointestinal adverse events, particularly nausea, were more frequent with cagrilintide. ^[1]

Later research evaluated cagrilintide with semaglutide. In REDEFINE 1, published in 2025, the estimated average change in body weight at 68 weeks was −20.4% in the combination group and −3.0% with placebo under the reported analysis. ^[3]

Those numbers describe the study groups and the study’s statistical approach. They are not an expected result for every individual, and they should not be presented as the effect of cagrilintide alone. The intervention contained semaglutide as well.

REDEFINE 2 studied a different population: adults with overweight or obesity and type 2 diabetes. The reported estimated average weight changes were −13.7% and −3.4% for the combination and placebo groups respectively at 68 weeks. ^[4] Differences between these trials illustrate why the participant population must travel with the result whenever it is quoted.

Reading a combination trial carefully

There are several distinct questions a study might address. Does the combination outperform placebo? Does it outperform either component alone? How tolerable is it? Does any difference persist? A positive answer to one question cannot be assumed to answer the others.

Comparisons across unrelated studies are especially vulnerable to overinterpretation. Trial duration, baseline characteristics, background support and treatment discontinuation can all affect the reported outcome. Even when two studies report percentages, they may not be estimating precisely the same thing.

It is also helpful to distinguish statistical significance from practical importance. A study needs to report the magnitude of the effect, the uncertainty around that estimate and the adverse events observed. A single percentage cannot summarise the whole benefit–risk balance.

What these studies do not establish

These results do not validate unsupervised combinations, supplier “stacks” or substitutions between research materials and trial medicines. The clinical programme concerns specified formulations used under trial protocols with eligibility criteria and monitoring.

Nor is a published phase 3 result itself a marketing authorisation. Regulatory decisions concern a defined product, indication and jurisdiction. This article describes research findings; it should not be read as a statement that cagrilintide or a supplier-labelled CAG product is available as an authorised UK treatment.

Why the topic matters

Cagrilintide provides a useful example of how metabolic research is broadening: from studying one signalling pathway to testing whether different pathways can be combined in a clinically useful way. The scientific interest lies in those carefully evaluated combinations, not in assuming that more ingredients must be better.

Sources and further reading

1. Lau et al.: cagrilintide phase 2 trial (2021)
2. Cagrilintide receptor structural study (2025)
3. REDEFINE 1: cagrilintide–semaglutide in overweight or obesity (2025)
4. REDEFINE 2: cagrilintide–semaglutide in type 2 diabetes (2025)

This article is provided for general educational purposes only. It is not medical advice and does not recommend the use, dose or sourcing of a prescription medicine or experimental compound. Consult an appropriately qualified healthcare professional about health concerns.

Explore the NŪVO research library

Hero image: conceptual scientific illustration; not a molecular model or evidence of a treatment effect.